C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
Open accessThe DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
Several emerging plasma biomarkers may ultimately prove useful in risk stratification and prognosis of cardiovascular disease. The clinical utility of these biomarkers will depend on their ability to provide a reflection of the underlying atherosclerotic burden or activity; the ability to provide reliable, accurate, and cost-effective information; and the ability to predict future events. High-sensitivity C-reactive protein (hs-CRP) fulfills many, if not all, of these criteria, and blood levels of hs-CRP are now commonly used in clinical practice to improve vascular risk prediction in primary and secondary prevention across all levels of low-density lipoprotein-cholesterol (LDL-C), all levels of the Framingham Risk Score, and all levels of metabolic syndrome. High-sensitivity C-reactive protein may also have clinical relevance as an adjunct to LDL-C for both the targeting and monitoring of statin therapy. Accumulating evidence suggests that several other selected emerging biomarkers may also potentially prove useful in the diagnosis and prognosis of cardiovascular disease. Specifically, data are accumulating on the potential clinical utility of lipoprotein-associated lipoprotein-associated phospholipase A2, myeloperoxidase, oxidized LDL, lipoprotein (a), isoprostanes, and small, dense LDL. This review focuses on hs-CRP and these emerging plasma biomarkers, and their potential diagnostic and prognostic utility in cardiovascular disease. Plasma biomarkers that reflect the clinical potential of atherothrombotic disease may allow more precise risk stratification and prognostication in high-risk populations, and perhaps earlier diagnosis and intervention in patients at risk for or with occult cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citationC-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citationDanesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513 · cited 1×
“ncident peripheral arterial disease (20,21).”
Self-citationThe Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,357
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citationRidker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
Self-citation
Cited by
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
“Plasma levels of C-reactive protein (CRP), an inflammatory marker that is predictive of a risk of myocardial infarction possibly greater than that estimated by traditional risk factor”
BackgroundAboyans, V., Criqui, M. H., Abraham, P., Allison, M. A., Creager, M. A., Diehm, C., Fowkes, F. G. R., Hiatt, W. R., Jönsson, B., Lacroix, P., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318276fbcb · Cited by 1,703
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Packard, R. R. S., & Libby, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097360 · Cited by 925
Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training
Roberts, C. K., Hevener, A. L., & Barnard, R. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c110062 · Cited by 831
Authors/Task Force Members, Poldermans, D., Bax, J. J., Boersma, E., De Hert, S., Eeckhout, E., Fowkes, G., Gorenek, B., Hennerici, M. G., Iung, B., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp337 · Cited by 738
Poldermans, D., Bax, J. J., Boersma, E., De Hert, S., Eeckhout, E., Fowkes, G., Gorenek, B., Hennerici, M. G., Iung, B., Kelm, M., et al. (2010) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e328334c017 · Cited by 683
Wang, Y., Lam, K. S. L., Kraegen, E. W., Sweeney, G., Zhang, J., Tso, A. W., Chow, W.-S., Wat, N. M., Xu, J. Y., Hoo, R. L., et al. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.075614 · Cited by 578
“Numerous epidemiologic studies have demonstrated that circulating hsCRP, an established marker of chronic inflammation, is an independent risk factor for T2DM as well as atherosclerotic heart diseases (35, 36).”
BackgroundMcMillan, D. C., Crozier, J. E. M., Canna, K., Angerson, W. J., & McArdle, C. S. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0259-6 · Cited by 533
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 317
Role of Inflammation in Atherosclerosis
Spagnoli, L. G., Bonanno, E., Sangiorgi, G., & Mauriello, A. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.038661 · Cited by 293
C-reactive protein and inflammation: conformational changes affect function
Wu, Y., Potempa, L. A., El Kebir, D., & Filep, J. G. (2015) · Biological Chemistry · doi:10.1515/hsz-2015-0149 · Cited by 285
Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease
Halaris, A. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_28 · Cited by 233
Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease?
Wilund, K. R. (2007) · Clinical Science · doi:10.1042/cs20060368 · Cited by 138
Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups
Joseph, J., Depp, C., Martin, A. S., Daly, R. E., Glorioso, D. K., Palmer, B. W., & Jeste, D. V. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.019 · Cited by 109
“Elevated CRP levels have been linked to multiple physical and lifestyle factors in non-psychiatric populations such as those with obesity (Rogowski et al., 2005), metabolic syndrome (Tsimikas et al., 2006), and smoking (Tracy et al., 1997; Dietrich et al., 2007).”
Zouaoui Boudjeltia, K., Faraut, B., Esposito, M. J., Stenuit, P., Dyzma, M., Van Antwerpen, P., Brohée, D., Vanhamme, L., Moguilevsky, N., Vanhaeverbeek, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028230 · Cited by 36
Cheng, Y., Li, J., Ren, X., Wang, D., Yang, Y., Miao, Y., Sheng, C., & Tian, J. (2021) · The Journal of Clinical Hypertension · doi:10.1111/jch.14314 · Cited by 25
Sucato, V., Corrado, E., Manno, G., Amata, F., Testa, G., Novo, G., & Galassi, A. R. (2022) · Angiology · doi:10.1177/00033197211034267 · Cited by 21
“In particular, oxidized LDL, which are formed in the artery walls due to the oxidative effect of ROS (reactive oxygen species), stimulates chronic inflammation and epicardial coronary atherosclerosis.(96) Moreover, LDL-C levels inversely correlate with CFR in hypercholesterolemic subjects; therefore, these particles m…”
Background
Metadata
- Authors
- Tsimikas, S., Willerson, J. T., & Ridker, P. M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2006-04
- Volume
- 47
- Issue
- 8
- Pages
- C19-C31
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2079307913
- Cited by
- 335
- References
- 132
- FWCI
- 39.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.